Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost;Évaluation de la température cutanée des patients atteints de sclérodermie traités périodiquement par iloprost

Revue du Rhumatisme (Edition Francaise)

Volumn 73, Issue 1, 2006, Pages 53-57

  Caramaschi, Paola ^a   Biasi, Domenico ^a   Canestrini, Sabrina ^a   Martinelli, Nicola ^a   Perbellini, Luigi ^b   Carletto, Antonio ^a   Pieropan, Sara ^a   Volpe, Alessandro ^a   Bambara, Lisa Maria ^a  

^a Dipartimento di Medicina Clinica e Sperimentale   (Italy)

^b Policlinico Universitario gB Rossi   (Italy)

Author keywords

Raynaud's phenomenon; Systemic sclerosis; Thermometry; Vasoactive therapy

Indexed keywords

EID: 32044464982     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2005.04.008     Document Type: Article

References (33)

1. A.L. Herrick Vascular function in systemic sclerosis Curr. Opin. Rheumatol. 12 2000 527 533
2. B. Marasini, M. Cugno, C. Bassani, M. Stanzani, B. Bottasso, and A. Agostoni Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon Int. J. Microcirc. Clin. Exp. 11 1992 375 382
3. M.B. Kahaleh Vascular involvement in systemic sclerosis (SSc) Clin. Exp. Rheumatol. 22 suppl. 2004 S19 S23
4. B. Kahaleh, O. Meyer, and R. Scorza Assessment of vascular involvement Clin. Exp. Rheumatol. 21 suppl. 2003 S9 S14
5. T.A. Medsger Jr., A.J. Silman, V.D. Steen, C.M. Black, A. Akesson, and P.A. Bacon A disease severity scale for systemic sclerosis: development and testing J. Rheumatol. 26 1999 2159 2167
6. M. Matucci-Cerinic, S. Generini, and A. Pignone New approaches to the treatment of Raynaud's phenomenon Curr. Opin. Rheumatol. 9 1997 544 556
7. A.L. Herrick, and S. Clark Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis Ann. Rheum. Dis. 57 1998 70 78
8. S. Clark, G. Dunn, T. Moore, M. Jayson 4th, T.A. King, and A.L. Herrick Comparison of thermography and laser doppler imaging in the assessment of Raynaud's phenomenon Microvasc. Res. 66 2003 73 76
9. G. Valentini, G. Leonardo, D.A. Moles, M.R. Arpaia, R. Maselli, and G. Tirri Transcutaneous oxygen pressure in systemic sclerosis; evaluation at different sensor temperatures and relationship to skin perfusion Arch. Dermatol. Res. 283 1991 285 288
10. M. Hahn, C. Hahn, K. Brauer, and M. Junger Skin thermoregulation during local cooling in healthy volunteers and patients with systemic sclerosis. Synchronous assessment of capillary red blood cell velocity, laser doppler flux and skin temperature Vasa 27 1998 3 9
11. C. Kan, S. Akimoto, M. Abe, K. Okada, and O. Ishikawa Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis Ann. Rheum. Dis. 61 2002 177 179
12. P. Caramaschi, O. Codella, G. Poli, L. Perbellini, D. Biasi, and L.M. Bambara Use of computerized digital thermometry for diagnosis of Raynaud's phenomenon Angiology 40 1989 863 871
13. O. Codella, P. Caramaschi, O. Olivieri, L. Perbellini, A. Perbellini, and L.M. Bambara Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon Angiology 40 1989 114 121
14. E.C. LeRoy, T. Krieg, C.M. Black, S. Jablonska, T. Krieg, and T.A. Medsger Scleroderma (systemic sclerosis): classification, subsets and pathogenesis J. Rheumatol. 15 1988 202 205
15. M. Bovenzi Finger thermometry in the assessment of subjects with vibration-induced white finger Scand. J. Work Environ. Health 13 1987 348 351
16. P. Caramaschi, D. Biasi, A. Carletto, T. Manzo, M. Randon, and S. Zeminian Finger skin temperature in patients affected by Raynaud's phenomenon with or without anticentromere antibody positivity Rheumatol. Int. 15 1996 217 220
17. A.L. Herrick, and M. Matucci Cerinic The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis Clin. Exp. Rheumatol. 19 2001 4 8
18. H.J. Torley, R. Madhok, H. Capell, R.M.L. Brouwer, P.J. Maddison, and C.M. Black A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases Ann. Rheum Dis.. 50 1991 800 804
19. F.M. Wigley, R.A. Wise, J.R. Seibold, D.A. McCloskey, and W.P. Dole Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis Ann. Intern. Med. 120 1994 199 206
20. H.R. Watson, and G. Belcher Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon Ann. Rheum. Dis. 50 1991 359 361
21. L. Bettoni, A. Geri, P. Airo, E. Danieli, I. Cavazzana, and C. Antonioli Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3:years Clin. Rheumatol. 21 2002 244 250
22. J. Pope, D. Fenlon, A. Thompson, B. Shea, D. Furst, and G. Wells Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis Cochrane Database Syst. Rev. 2 2000 (CD000953)
23. S. Della Bella, M. Molteni, C. Mocellin, S. Fumagalli, P. Bonara, and R. Scorza Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules Prostaglandins Other Lipid Mediat. 65 2001 73 83
24. G. Filaci, M. Cutolo, M. Scudeletti, C. Castagneto, L. Derchi, and R. Gianrossi Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12:months of therapy Rheumatolology 38 1999 992 996
25. S. Della Bella, M. Molteni, B. Mascagni, C. Zulian, S. Compasso, and R. Scorza Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine Clin. Exp. Rheumatol. 15 1997 135 141
26. V. Kahari, J. Heini, and E. Vuorio Interleukin 1 increases collagen production and mRNA levels in cultured skin fibroblasts Biochim. Biophys. Acta 929 1987 142 147
27. M. Duncan, and B. Berman Stimulation of collagen and glycosaminiglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6 J. Invest. Dermatol. 97 1991 686 692
28. R. Stratton, X. Shiwen, G. Martini, A. Holmes, A. Leask, and T. Haberberger Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients J. Clin. Invest. 108 2001 241 250
29. A. Mazzone, P. Faggioli, C. Cusa, C. Stefanin, M. Rondena, and B. Morelli Effects of iloprost on adhesion molecules and F1 + 2 in peripheral ischemia Eur. J. Clin. Invest. 32 2002 882 888
30. M.A. Öztürk, S. Haznedaroglu, Y. Karaaslan, B. Goker, and I.C. Haznedaroglu Increased serum thrombopoietin concentration in systemic sclerosis associated with myelofibrosis and thrombocytosis Joint Bone Spine 2006 (in press)
31. M. Rademaker, R.H. Thomas, G. Provost, J.A. Beachman, E.D. Cooke, and J.D. Kirby Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis Postgrad. Med. J. 63 1987 617 620
32. R. Scorza, M. Caronni, B. Mascagni, V. Berruti, S. Bazzi, and E. Micallef Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study Clin. Exp. Rheumatol. 19 2001 503 508
33. P. Caramaschi, D. Biasi, M. Ferrari, A. Volpe, N. Martinelli, and A. Carletto Long-term evaluation of the lung function in patients affected by scleroderma treated with cyclic iloprost infusions Rheumatol. Int. 25 2005 250 254